Home › Trials › NCT06795113
Clinical trial Recruiting at 1 site Observational Ages 18 to 100

New methods for evaluating lymphoma treatment response using PET/CT imaging

Official title: Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma

Run by Ruijin Hospital · NCT06795113 · Data updated 2026-11-12

This study is testing a new way to see how well lymphoma treatments are working by looking at PET/CT scans from 4,000 patients to help doctors make better decisions about care.

Quick facts

Study typeObservational
Ages18 Years to 100 Years
SexAll
Enrollment4000 (estimated)
SponsorRuijin Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJune 1, 2013
Main results expectedDecember 31, 2029
Study endsDecember 31, 2029
Registry record updatedJanuary 27, 2025
Trial IDNCT06795113 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with histopathologically confirmed high-metabolic lymphoma who have undergone 18F-FDG PET/CT imaging at various treatment stages.

Probably not a fit

Patients with a history of prior antitumor treatment or other concurrent malignancies may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a novel approach for assessing treatment response in patients with high-metabolic lymphoma by analyzing PET/CT imaging data. It involves a multicenter retrospective cohort design, utilizing data from 2,000 patients treated at Ruijin Hospital and an additional 2,000 patients from other institutions. The study compares end-of-treatment PET results with interim PET results to establish a new response assessment method, contrasting it with the existing Lugano classification criteria. The goal is to provide clinicians with more accurate tools for evaluating treatment efficacy and predicting patient prognosis.

Why it matters

Potential benefit: If successful, this study could lead to more accurate evaluations of treatment response in lymphoma, improving patient management and outcomes.

How similar studies have gone: Other studies have shown success in using PET/CT imaging for lymphoma assessment, but this specific approach is novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Histopathologically confirmed high-metabolic lymphoma
2. Underwent 18F-FDG PET/CT imaging before, during, and after treatment
3. Treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations
4. Complete clinicopathological and follow-up data available Exclusion Criteria

1: History of prior antitumor treatment 2: History of other malignancies 3: Incomplete clinical data or imaging records 4: Presence of other concurrent malignant tumors

Where it's running

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
    Shanghai, Shanghai Municipality, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Lymphoma 394Ruijin Hospital 182
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.